Early Diagnosis of Chemotherapy-Linked Cardiotoxicity in Breast Cancer Patients Using Conventional Biomarker Panel: A Prospective Study Protocol
Authors:
- Saule BalmagambetovaSBSaule Balmagambetova
- Zhenisgul TlegenovaZTZhenisgul Tlegenova
- Bekbolat ZholdinBZBekbolat Zholdin
- Gulnara KurmanalinaGKGulnara Kurmanalina
- Iliada TalipovaITIliada Talipova
- Arip KoyshybaevAKArip Koyshybaev
- Dinara NurmanovaDNDinara Nurmanova
- Gulmira SultanbekovaGSGulmira Sultanbekova
- Mira BaspayevaMBMira Baspayeva
- Saule MadinovaSMSaule Madinova
- Kulparshan KubenovaKKKulparshan Kubenova
- Ainel UrazovaAUAinel Urazova
Open Access
- 6 November 2022
- journal article
- research article
- Published by MDPI AG in Diagnostics
- Vol. 12 (11) , 2714
Abstract
The prognosis of cancer treatment depends on, among other aspects, the cardiotoxicity of chemotherapy. This research aims to create a feasible algorithm for the early diagnosis of antitumor therapy cardiotoxicity in breast cancer patients. The paper represents a protocol for a prospective cohort study with N 120 eligible participants admitted for treatment with anthracyclines and/or trastuzumab. These patients will be allocated into four risk groups regarding potential cardiotoxic complications. Patients will be examined five times every three months for six biomarkers: cardiac troponin I (cTnI), brain natriuretic peptide (BNP), C-reactive protein (CRP), myeloperoxidase (MPO), galectin-3 (Gal-3), and D-dimer, simultaneously with echocardiographic methods, including speckle tracking. The adjusted relative risk (aOR) of interrupting an entire course of chemotherapy due to cardiotoxic events will be assessed using multiple analyses of proportional Cox risks. The Cox model will also assess associations between baseline biomarker values and time to cardiotoxic events. Moreover, partly conditional survival models will be applied to determine associations between repeated assessments of changes in biomarkers from baseline and time to cancer therapy-related cardiac dysfunction. All models will be adjusted for cancer therapy regimen, baseline LVEF, groups at risk, baseline biomarker values, and age. The decision-tree and principal component analysis (PCA) methods will also be applied. Thus, feasible patterns will be detected.Keywords
Funding Information
- Science Committee of the Ministry of Education and Science of the Republic of Kazakhstan (IRN AP09259524, state reg. No. 0121PK00565)
This publication has 55 references indexed in Scilit:
- 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice GuidelinesEuropean Heart Journal, 2016
- Cancer Therapy–Related Cardiac Dysfunction and Heart FailureCirculation: Heart Failure, 2016
- High sensitivity cardiac troponin and the under-diagnosis of myocardial infarction in women: prospective cohort studyBMJ, 2015
- High sensitivity cardiac troponin assays in the clinical laboratoriesClinical Chemistry and Laboratory Medicine (CCLM), 2015
- Use of Myocardial Strain Imaging by Echocardiography for the Early Detection of Cardiotoxicity in Patients During and After Cancer ChemotherapyJACC, 2014
- The ratio of d-dimer to brain natriuretic peptide may help to differentiate between cerebral infarction with and without acute aortic dissectionJournal of the Neurological Sciences, 2014
- Perioperative Assessment of Myocardial DeformationAnesthesia & Analgesia, 2014
- Assessment of Echocardiography and Biomarkers for the Extended Prediction of Cardiotoxicity in Patients Treated With Anthracyclines, Taxanes, and TrastuzumabCirculation: Cardiovascular Imaging, 2012
- Cardiac biomarkers: New tools for heart failure management2012
- Drug Compliance in Therapeutic TrialsControlled Clinical Trials, 1998